Literature DB >> 9688900

Ischemic tolerance in skeletal muscle: role of nitric oxide.

S Pudupakkam1, K A Harris, W G Jamieson, G DeRose, J A Scott, M W Carson, M G Schlag, P R Kvietys, R F Potter.   

Abstract

We tested the hypothesis that ischemic preconditioning (PC) of skeletal muscle provided tolerance to a subsequent ischemic event 24 h later, and that such protection was due to nitric oxide (NO). Male Wistar rats, anesthetized with halothane, were randomly assigned to groups: ischemic (no PC; n = 11), PC (n = 11), PC + N-nitro-L-arginine methyl ester (L-NAME; 100 micromol/l; n = 5), PC + N-nitro-D-arginine methyl ester (100 micromol/l; n= 4), PC + aminoguanidine (AMG; 100 micromol/l; n = 4), ischemic + L-NAME (n= 4), or ischemic + AMG (n = 4). PC consisted of 5x 10 min of ischemia and reperfusion, and, 24 h later, 2 h of ischemia were induced by a tourniquet applied to the limb. With the use of intravital microscopy, the number of perfused capillaries (Npc) in the extensor digitorum longus (EDL) muscle was measured over a 90-min reperfusion period. The ratio of ethidium bromide- to bisbenzimide-labeled nuclei was used to estimate tissue injury. PC preserved Npc (23.6 +/- 2.5) following 2 h of ischemia compared with sham muscles (11.5 +/- 5.1), significantly elevating inducible NO synthase (iNOS) activity (81% increase), but did not afford protection to the parenchyma. L-NAME and AMG prevented ischemia-reperfusion-induced reduction in Npc in muscles without PC. However, after 90 min of reperfusion, L-NAME (Npc = 15.0 +/- 1.7), but not AMG (Npc = 22.8 +/- 3.1), significantly reduced the microvascular protection afforded by PC. We conclude that PC of the EDL muscle resulted, 24 h later, in protection to microvascular perfusion only, and that such protection was due to NO from sources other than iNOS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688900     DOI: 10.1152/ajpheart.1998.275.1.H94

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Effects of ischemic preconditioning on economy, VO2 kinetics and cycling performance in endurance athletes.

Authors:  A E Kilding; G M Sequeira; M R Wood
Journal:  Eur J Appl Physiol       Date:  2018-10-25       Impact factor: 3.078

Review 2.  Role of priming stresses and Hsp70 in protection from ischemia-reperfusion injury in cardiac and skeletal muscle.

Authors:  D A Lepore; K R Knight; R L Anderson; W A Morrison
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

3.  Two episodes of remote ischemia preconditioning improve motor and sensory function of hind limbs after spinal cord ischemic injury.

Authors:  Salah Omar Bashir; Mohamed Darwesh Morsy; Dalia Fathy El Agamy
Journal:  J Spinal Cord Med       Date:  2019-04-15       Impact factor: 1.985

4.  Early iNOS impairment and late eNOS enhancement during reperfusion following 2.49 MHz continuous ultrasound exposure after ischemia.

Authors:  C Makena Hightower; Marcos Intaglietta
Journal:  Ultrason Sonochem       Date:  2008-05-24       Impact factor: 7.491

5.  Ischemic preconditioning attenuates capillary no-reflow and leukocyte adherence in postischemic pancreatitis.

Authors:  R Obermaier; E von Dobschuetz; O Drognitz; U T Hopt; S Benz
Journal:  Langenbecks Arch Surg       Date:  2004-01-09       Impact factor: 3.445

Review 6.  The Effects of Ischemic Preconditioning on Human Exercise Performance.

Authors:  Anthony V Incognito; Jamie F Burr; Philip J Millar
Journal:  Sports Med       Date:  2016-04       Impact factor: 11.136

7.  Chronic lower extremity ischemia: a human model of ischemic tolerance.

Authors:  Amit Badhwar; Thomas L Forbes; Marge B Lovell; Alison A Dungey; Sarah D McCarter; Jeffrey R Scott; Guy DeRose; Kenneth A Harris; Richard F Potter
Journal:  Can J Surg       Date:  2004-10       Impact factor: 2.089

8.  Nitric Oxide is Necessary for Diazoxide Protection Against Ischemic Injury in Skeletal Muscle.

Authors:  Hossein Farahini; Marjan Ajami; Jalaledin Mirzay Razaz; Nahid Azad; Mansooreh Soleimani; Seyyed Abdulmajid Ayatollahi; Nahid Abotaleb; Habibolah Peyrovi; Hamidreza Pazoki-Toroudi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.